The Precision Medicine Company
Developing microbiome-based predictive diagnostic and companion therapeutic products to enable safer and more efficacious drug therapies
UK-wide online survey of people with IBD confirms strong patient support for AlphaBiomics’
predictive diagnostic RxSelex™. Read more here.
The Precision Medicine Company
Developing microbiome-based predictive diagnostic and companion therapeutic products to enable safer and more efficacious drug therapies
Winner of the 2018 European Innovation Quickfire Challenge (read more)